Alembic Gets USFDA Nod for Binimetinib Tablets
Alembic’s Binimetinib Tablets are generic equivalents of Mektovi and are indicated, in combination with encorafenib, for treating certain patients with advanced melanoma and metastatic non-small cell lung cancer (NSCLC) carrying specific BRAF mutations.


